Acquired genomic aberrations associated with methotrexate resistance vary with background genomic instability

Antoine M. Snijders, Mario A. Hermsen, Joshua Baughman, Tineke E. Buffart, Bing Huey, Pavla Gajduskova, Ritu Roydasgupta, Taku Tokuyasu, Gerrit A. Meijer, Jane Fridlyand, Donna Albertson

Research output: Contribution to journalArticle

Abstract

Tumors vary widely in chromosomal level genome instability. To gain a better understanding of the underlying defects which foster specific types of aberrations, we investigated the response of cells of related genetic backgrounds to challenge with methotrexate. We studied mismatch repair deficient HCT116 cells, two derivatives also deficient in XRCC5 (HCT116 Ku86+/-) or BLM (HCT116 BLM-/-), and mismatch repair competent HCT116+chr3 cells. We show that colony formation occurred at a significantly higher frequency in HCT116 cells and HCT116 Ku86+/- cells compared to HCT116 BLM-/- and HCT116+chr3 cells. Visible colonies arose most rapidly in HCT116 Ku86+/- cells, whereas they formed most slowly in HCT116+chr3 cells. Copy number changes acquired by the methotrexate resistant HCT116 and HCT116 BLM-/- cells most often included whole chromosome gains or losses or no acquired copy number changes, whereas resistance in HCT116+chr3 and HCT116 Ku86+/- cells was associated with amplification of DHFR and copy number transitions leading to increased copy number of DHFR, respectively. The additional copies of DHFR were present on unstable chromosomes and organized as inverted repeats in HCT116+chr3 cells, while they were most often present as direct repeats in HCT116 Ku86+/- cells. These observations suggest that different mutational mechanisms promote drug resistance in these genetic backgrounds; mismatch repair deficiency in HCT116, high rates of chromosomal instability in HCT116 Ku86+/-, and low rates of chromosomal instability in HCT116+chr3. On the other hand, it appears that loss of BLM function suppresses the mismatch repair mutator mechanism in mismatch repair and BLM deficient HCT116 BLM-/- cells.

Original languageEnglish (US)
Pages (from-to)71-83
Number of pages13
JournalGenes Chromosomes and Cancer
Volume47
Issue number1
DOIs
StatePublished - Jan 2008

Fingerprint

HCT116 Cells
Genomic Instability
Methotrexate
DNA Mismatch Repair
Chromosomal Instability
Chromosomes
Nucleic Acid Repetitive Sequences
Drug Resistance

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Acquired genomic aberrations associated with methotrexate resistance vary with background genomic instability. / Snijders, Antoine M.; Hermsen, Mario A.; Baughman, Joshua; Buffart, Tineke E.; Huey, Bing; Gajduskova, Pavla; Roydasgupta, Ritu; Tokuyasu, Taku; Meijer, Gerrit A.; Fridlyand, Jane; Albertson, Donna.

In: Genes Chromosomes and Cancer, Vol. 47, No. 1, 01.2008, p. 71-83.

Research output: Contribution to journalArticle

Snijders, AM, Hermsen, MA, Baughman, J, Buffart, TE, Huey, B, Gajduskova, P, Roydasgupta, R, Tokuyasu, T, Meijer, GA, Fridlyand, J & Albertson, D 2008, 'Acquired genomic aberrations associated with methotrexate resistance vary with background genomic instability', Genes Chromosomes and Cancer, vol. 47, no. 1, pp. 71-83. https://doi.org/10.1002/gcc.20509
Snijders, Antoine M. ; Hermsen, Mario A. ; Baughman, Joshua ; Buffart, Tineke E. ; Huey, Bing ; Gajduskova, Pavla ; Roydasgupta, Ritu ; Tokuyasu, Taku ; Meijer, Gerrit A. ; Fridlyand, Jane ; Albertson, Donna. / Acquired genomic aberrations associated with methotrexate resistance vary with background genomic instability. In: Genes Chromosomes and Cancer. 2008 ; Vol. 47, No. 1. pp. 71-83.
@article{64cc06befdcd4b6abf506bc6f67638ba,
title = "Acquired genomic aberrations associated with methotrexate resistance vary with background genomic instability",
abstract = "Tumors vary widely in chromosomal level genome instability. To gain a better understanding of the underlying defects which foster specific types of aberrations, we investigated the response of cells of related genetic backgrounds to challenge with methotrexate. We studied mismatch repair deficient HCT116 cells, two derivatives also deficient in XRCC5 (HCT116 Ku86+/-) or BLM (HCT116 BLM-/-), and mismatch repair competent HCT116+chr3 cells. We show that colony formation occurred at a significantly higher frequency in HCT116 cells and HCT116 Ku86+/- cells compared to HCT116 BLM-/- and HCT116+chr3 cells. Visible colonies arose most rapidly in HCT116 Ku86+/- cells, whereas they formed most slowly in HCT116+chr3 cells. Copy number changes acquired by the methotrexate resistant HCT116 and HCT116 BLM-/- cells most often included whole chromosome gains or losses or no acquired copy number changes, whereas resistance in HCT116+chr3 and HCT116 Ku86+/- cells was associated with amplification of DHFR and copy number transitions leading to increased copy number of DHFR, respectively. The additional copies of DHFR were present on unstable chromosomes and organized as inverted repeats in HCT116+chr3 cells, while they were most often present as direct repeats in HCT116 Ku86+/- cells. These observations suggest that different mutational mechanisms promote drug resistance in these genetic backgrounds; mismatch repair deficiency in HCT116, high rates of chromosomal instability in HCT116 Ku86+/-, and low rates of chromosomal instability in HCT116+chr3. On the other hand, it appears that loss of BLM function suppresses the mismatch repair mutator mechanism in mismatch repair and BLM deficient HCT116 BLM-/- cells.",
author = "Snijders, {Antoine M.} and Hermsen, {Mario A.} and Joshua Baughman and Buffart, {Tineke E.} and Bing Huey and Pavla Gajduskova and Ritu Roydasgupta and Taku Tokuyasu and Meijer, {Gerrit A.} and Jane Fridlyand and Donna Albertson",
year = "2008",
month = "1",
doi = "10.1002/gcc.20509",
language = "English (US)",
volume = "47",
pages = "71--83",
journal = "Genes Chromosomes and Cancer",
issn = "1045-2257",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Acquired genomic aberrations associated with methotrexate resistance vary with background genomic instability

AU - Snijders, Antoine M.

AU - Hermsen, Mario A.

AU - Baughman, Joshua

AU - Buffart, Tineke E.

AU - Huey, Bing

AU - Gajduskova, Pavla

AU - Roydasgupta, Ritu

AU - Tokuyasu, Taku

AU - Meijer, Gerrit A.

AU - Fridlyand, Jane

AU - Albertson, Donna

PY - 2008/1

Y1 - 2008/1

N2 - Tumors vary widely in chromosomal level genome instability. To gain a better understanding of the underlying defects which foster specific types of aberrations, we investigated the response of cells of related genetic backgrounds to challenge with methotrexate. We studied mismatch repair deficient HCT116 cells, two derivatives also deficient in XRCC5 (HCT116 Ku86+/-) or BLM (HCT116 BLM-/-), and mismatch repair competent HCT116+chr3 cells. We show that colony formation occurred at a significantly higher frequency in HCT116 cells and HCT116 Ku86+/- cells compared to HCT116 BLM-/- and HCT116+chr3 cells. Visible colonies arose most rapidly in HCT116 Ku86+/- cells, whereas they formed most slowly in HCT116+chr3 cells. Copy number changes acquired by the methotrexate resistant HCT116 and HCT116 BLM-/- cells most often included whole chromosome gains or losses or no acquired copy number changes, whereas resistance in HCT116+chr3 and HCT116 Ku86+/- cells was associated with amplification of DHFR and copy number transitions leading to increased copy number of DHFR, respectively. The additional copies of DHFR were present on unstable chromosomes and organized as inverted repeats in HCT116+chr3 cells, while they were most often present as direct repeats in HCT116 Ku86+/- cells. These observations suggest that different mutational mechanisms promote drug resistance in these genetic backgrounds; mismatch repair deficiency in HCT116, high rates of chromosomal instability in HCT116 Ku86+/-, and low rates of chromosomal instability in HCT116+chr3. On the other hand, it appears that loss of BLM function suppresses the mismatch repair mutator mechanism in mismatch repair and BLM deficient HCT116 BLM-/- cells.

AB - Tumors vary widely in chromosomal level genome instability. To gain a better understanding of the underlying defects which foster specific types of aberrations, we investigated the response of cells of related genetic backgrounds to challenge with methotrexate. We studied mismatch repair deficient HCT116 cells, two derivatives also deficient in XRCC5 (HCT116 Ku86+/-) or BLM (HCT116 BLM-/-), and mismatch repair competent HCT116+chr3 cells. We show that colony formation occurred at a significantly higher frequency in HCT116 cells and HCT116 Ku86+/- cells compared to HCT116 BLM-/- and HCT116+chr3 cells. Visible colonies arose most rapidly in HCT116 Ku86+/- cells, whereas they formed most slowly in HCT116+chr3 cells. Copy number changes acquired by the methotrexate resistant HCT116 and HCT116 BLM-/- cells most often included whole chromosome gains or losses or no acquired copy number changes, whereas resistance in HCT116+chr3 and HCT116 Ku86+/- cells was associated with amplification of DHFR and copy number transitions leading to increased copy number of DHFR, respectively. The additional copies of DHFR were present on unstable chromosomes and organized as inverted repeats in HCT116+chr3 cells, while they were most often present as direct repeats in HCT116 Ku86+/- cells. These observations suggest that different mutational mechanisms promote drug resistance in these genetic backgrounds; mismatch repair deficiency in HCT116, high rates of chromosomal instability in HCT116 Ku86+/-, and low rates of chromosomal instability in HCT116+chr3. On the other hand, it appears that loss of BLM function suppresses the mismatch repair mutator mechanism in mismatch repair and BLM deficient HCT116 BLM-/- cells.

UR - http://www.scopus.com/inward/record.url?scp=36549043874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36549043874&partnerID=8YFLogxK

U2 - 10.1002/gcc.20509

DO - 10.1002/gcc.20509

M3 - Article

C2 - 17943968

AN - SCOPUS:36549043874

VL - 47

SP - 71

EP - 83

JO - Genes Chromosomes and Cancer

JF - Genes Chromosomes and Cancer

SN - 1045-2257

IS - 1

ER -